# US 2006/0041147 A1 · Method for preparing irbesartan and intermediates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0041147 A1
- Document ID: US20060041147A1
- Status: Published application
- Kind: A1
- Application number: 11/209,000
- Filed: 2005-08-22
- Published: 2006-02-23
- Earliest claimed: 2004-08-23
- Assignees: Bristol-Myers Squibb Company
- Inventors: Edgar Miranda; Cornelis Vlaar; Jingyang Zhu
- Web page: https://patentgrep.com/patent/US20060041147A1

## CPC

- C07D 235/02: condensed with carbocyclic rings or ring systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for preparing irbesartan and intermediates thereof. Irbesartan has the structure of formula I,

## Claims

### Claim 1

A method for preparing a compound of formula II, or a pharmaceutically acceptable salt thereof,
comprising reacting a mixture of a compound of formula IVa and a compound of formula IVb, and optionally a compound of formula IVc,
with a compound of formula V, or a pharmaceutically acceptable salt thereof,
in the presence of a base and a reducing agent, and optionally in the presence of a phase transfer catalyst; and
further optionally, converting the compound of formula II into a pharmaceutically acceptable salt.

### Claim 2 (depends on 1)

The method of claim 1, wherein said reducing agent is dialkly phosphite.

### Claim 3 (depends on 1)

The method of claim 1, wherein said pharmaceutically acceptable salt of formula V is HCl.

### Claim 4 (depends on 1)

The method of claim 1, in which at least one aqueous base is used in the presence of said phase transfer catalyst.

### Claim 5 (depends on 4)

The method of claim 4, wherein said aqueous base is aqueous KOH, aqueous NaOH, or aqueous LiOH, said phase transfer catalyst is tetra-alkylammonium chloride, said reducing agent is dialkly phosphite, and said pharmaceutically acceptable salt of formula V is HCl.

### Claim 6 (depends on 5)

The method of claim 5, wherein said tetra-alkylammonium chloride is methyl-tri-n-butyl ammonium chloride, and said dialkly phosphite is diethyl phosphite.

### Claim 7 (depends on 1)

The method of claim 1, wherein the compound of formula II is crystallized from at least one solvent selected from methyl tert-butyl ether and iso-propanol.

### Claim 8 (depends on 5)

The method of claim 5, wherein the compound of formula II is crystallized from at least one solvent selected from methyl tert-butyl ether and iso-propanol.

### Claim 9 (depends on 7)

The method of claim 7, further comprising washing the compound of formula II with at least one solvent selected from methyl tert-butyl ether and iso-propanol, and recycling the washed solvent to crystallize the compound of formula II as recited in claim 7.

### Claim 10 (depends on 8)

The method of claim 8, further comprising washing the compound of formula II with at least one solvent selected from methyl tert-butyl ether and iso-propanol, and recycling the washed solvent to crystallize the compound of formula II as recited in claim 8.

### Claim 11 (depends on 1)

The method of claim 1, further comprising converting the compound of formula II to a compound of formula I, or a pharmaceutically acceptable salt thereof,

### Claim 12 (depends on 11)

The method of claim 11, wherein said reducing agent is diakyl phosphite.

### Claim 13 (depends on 11)

The method of claim 11, wherein said pharmaceutically acceptable salt of formula V is HCl.

### Claim 14 (depends on 11)

The method of claim 11, in which at least one aqueous base is used in the presence of said phase transfer catalyst.

### Claim 15 (depends on 14)

The method of claim 14, wherein said aqueous base is aqueous KOH, aqueous NaOH, or aqueous LiOH, said phase transfer catalyst is tetra-alkylammonium chloride, said reducing agent is dialkly phosphite, and said pharmaceutically acceptable salt of formula V is HCl.

### Claim 16 (depends on 15)

The method of claim 15, wherein said tetra-alkylammonium chloride is methyl-tri-n-butyl ammonium chloride, and said dialkly phosphite is diethyl phosphite.

### Claim 17 (depends on 11)

The method of claim 11, wherein the conversion is achieved by reacting the compound of formula II with sodium azide.

### Claim 18 (depends on 17)

The method of claim 17, wherein said reducing agent is diakyl phosphite.

### Claim 19 (depends on 17)

The method of claim 17 wherein said pharmaceutically acceptable salt of formula V is HCl.

### Claim 20 (depends on 17)

The method of claim 17, in which at least one aqueous base is used in the presence of said phase transfer catalyst.

### Claim 21 (depends on 20)

The method of claim 20, wherein said aqueous base is aqueous KOH, aqueous NaOH, or aqueous LiOH, said phase transfer catalyst is tetra-alkylammonium chloride, said reducing agent is dialkly phosphite, and said pharmaceutically acceptable salt of formula V is HCl.

### Claim 22 (depends on 21)

The method of claim 21, wherein said tetra-alkylammonium chloride is methyl-tri-n-butyl ammonium chloride, and said dialkly phosphite is diethyl phosphite.

### Claim 23

A method for preparing a compound of formula II in substantially pure form,
comprising:
(a) crystallizing a crude compound of formula II with at least one solvent selected from methyl tert-butyl ether and iso-propanol to give a compound of formula II in crystal form;
(b) washing the compound of formula II in crystal form from step (a) with at least one solvent selected from methyl tert-butyl ether and iso-propanol to give the compound of formula II in substantially pure form; and
(c) recycling the washed solvent collected from step (b) to crystallize a crude compound of formula II in the next batch as recited in step (a).

### Claim 24 (depends on 23)

The method of claim 23, wherein said solvent in steps (a), (b) and (c) is methyl tert-butyl ether.

### Claim 25 (depends on 23)

The method of claim 23, wherein said solvent in steps (a), (b) and (c) is iso-propanol.
